Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Roquefort Investments PLC

Healthcare GB ROQ

NoneGBX
0.00(0%)

Last update at 2026-06-03T16:00:51.911650Z

Day Range

--
LowHigh

52 Week Range

0.009530.00
LowHigh

Fundamentals

  • Previous Close 11.30
  • Market Cap0.16M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.92673M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.21457M -1.93223M -1.63430M -
Minority interest - - - -
Net income -0.97180M -1.74454M -1.61542M -
Selling general administrative 0.94M 1.51M 0.94M -
Selling and marketing expenses - 0.87M - -
Gross profit -0.01600M 0.20M 0.00000M -
Reconciled depreciation 0.00540M 0.00389M 0.00000M -
Ebit -1.11692M -1.93223M -1.63430M -0.38298M
Ebitda -1.11152M -1.92834M -1.63430M -
Depreciation and amortization 0.00540M 0.00389M 0.00000M -
Non operating income net other - - - -
Operating income -1.11152M -1.93364M -1.63430M -
Other operating expenses 1.11M 2.13M 1.63M -
Interest expense 0.10M 0.00006M - 0.00000M
Tax provision -0.24277M -0.18769M -0.01889M -
Interest income 0.00000M 0.00147M - -
Net interest income -0.09765M 0.00141M - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.24M -0.18769M -0.01889M -
Total revenue 0.00000M 0.20M 0.00000M -
Total operating expenses 1.10M 2.13M 1.63M -
Cost of revenue 0.02M 0.00389M 0.00000M -
Total other income expense net -0.10305M 0.00141M - -
Discontinued operations - - - -
Net income from continuing ops -0.97180M -1.74454M -1.61542M -
Net income applicable to common shares - - -1.61542M -0.68807M
Preferred stock and other adjustments - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.75M 6.09M 7.77M 4.56M
Intangible assets 5.06M 5.06M 5.06M 1.20M
Earning assets - - - -
Other current assets - 0.16M - -
Total liab 0.86M 0.59M 0.56M 0.48M
Total stockholder equity 4.89M 5.50M 7.21M 4.08M
Deferred long term liab - - - -
Other current liab 0.16M 0.16M 0.21M 0.15M
Common stock 1.36M 1.29M 1.29M 0.72M
Capital stock 1.36M 1.29M 1.29M 0.72M
Retained earnings -5.26507M -4.29327M -2.54873M -0.91432M
Other liab - - 0.28M 0.28M
Good will 0.28M 0.28M 0.28M 0.28M
Other assets - - - -
Cash 0.34M 0.54M 2.32M 0.90M
Cash and equivalents - - - -
Total current liabilities 0.58M 0.31M 0.28M 0.20M
Current deferred revenue - - - -
Net debt 0.06M -0.53732M -2.32297M -0.89972M
Short term debt 0.40M - - -
Short long term debt 0.40M 0.00000M - -
Short long term debt total 0.40M - - -
Other stockholder equity 4.62M 4.40M 8.46M 4.28M
Property plant equipment - - - -
Total current assets 0.36M 0.69M 2.42M 3.08M
Long term investments - - - -
Net tangible assets - - 1.86M 2.60M
Short term investments - - - -
Net receivables 0.03M 0.16M 0.10M 2.15M
Long term debt - - - -
Inventory - -0.15759M - -
Accounts payable 0.02M 0.14M 0.07M 0.04M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 4.18M 4.10M - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - 5.06M - -
Deferred long term asset charges - - - -
Non current assets total 5.39M 5.39M 5.34M 1.48M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -0.05257M -0.10348M -
Change to liabilities - - 0.06M 0.10M
Total cashflows from investing activities - -0.05257M -0.10348M -0.82967M
Net borrowings 0.58M 0.00000M - -
Total cash from financing activities 0.58M -0.00006M 3.10M 3.47M
Change to operating activities - - - -
Net income -1.21457M -1.74454M -1.63430M -0.68807M
Change in cash -0.20021M -1.78565M 1.42M 0.67M
Begin period cash flow 0.54M 2.32M 0.90M -
End period cash flow 0.34M 0.54M 2.32M 0.90M
Total cash from operating activities -0.78373M -1.73353M -1.57748M -1.96728M
Issuance of capital stock - - 3.12M -
Depreciation 0.00540M 0.00389M 0.00000M -
Other cashflows from investing activities - 0.00147M - -
Dividends paid - - - -
Change to inventory - - 0.00000M 0.00696M
Change to account receivables 0.13M -0.05585M -0.02032M -1.59798M
Sale purchase of stock - - - -
Other cashflows from financing activities - -0.00006M -0.01899M -0.11955M
Change to netincome - - -0.00149M 0.21M
Capital expenditures 0.00000M 0.05M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.00927M -0.02841M 0.04M -
Stock based compensation 0.02M 0.01M 0.00843M -
Other non cash items 0.39M 0.03M 0.00897M -
Free cash flow -0.78373M -1.78757M -1.57748M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ROQ
Roquefort Investments PLC		 - -% - - - 23.25 0.29 20.56 -2.6683
GNS
Genus PLC		 -4.0 0.18% 2236.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -1.7 1.25% 134.50 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 -3.0 0.52% 572.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -5.0 6.67% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.

Roquefort Investments PLC

85 Great Portland Street, London, United Kingdom, W1W 7LT

Key Executives

Name Title Year Born
Mr. Stephen Paul West B.Com, CA Exec. Chairman 1973
Mr. Trevor Ajanthan Reginald CEO & Exec. Director NA
Prof. Martin J. Evans FRS Group Chief Scientific Officer & Exec. Director NA
Dr. Armand Keating M.D. Independent Chief Medical Officer NA
Mr. Stephen Paul West B.Com, CA Executive Chairman 1972
Dr. Darrin Matthew Disley O.B.E., Ph.D. Interim MD & Director 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.